Agios Pharmaceuticals Stock News

– In Adults with Pyruvate Kinase (PK) Deficiency Who Are Not Regularly Transfused, PYRUKYND® Significantly Increased Hemoglobin Level, Decreased Hemolysis and Improved Patient-Reported Outcomes –

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) shares, rose in value on Friday, 03/11/22, with the stock price down by -8.66% to the previous day’s close as strong demand from buyers drove the stock to $28.70. Actively observing the price movement in the last trading, the stock closed the session at $31.42, falling within a range of $28.65 … Looking For A Top Momentum Stock? Why Agios Pharmaceuticals Inc. (NASDAQ: AGIO) Is A Great Pick Read More »

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) price on Friday, March 04, fall -1.87% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $31.53. A look at the stock’s price movement, the close in the last trading session was $32.13, moving within a range at $31.375 and $32.70. The beta value … Agios Pharmaceuticals Inc.’s (AGIO) Stock Is Harder To Predict Than You Think Read More »

The Food and Drug Administration approval calendar was light in February. Nevertheless, the month saw regulatory nods accorded to some breakthrough therapies. Agios Pharmaceuticals, Inc.'s (NASDAQ: AG

The Food and Drug Administration approval calendar was light in February. Nevertheless, the month saw regulatory nods accorded to some breakthrough therapies. Agios Pharmaceuticals, Inc.''s (NASDAQ: AGIO ) Pyrukynd (mitapivat) was approved for the treatment of hemolytic anemia in people with pyruvate kinase deficiency. Hemolysis refers to the destruction of red blood cells. Pyrukynd is a "new molecular entity," a term that refers to a drug containing an active moiety that hasn''t been previously approved by the FDA. NME approval, therefore, is considered a measure of innovation in drug research. Another NME that passed the FDA hurdle was Sanofi''s (NASDAQ: SNY ) Enjaymo for the treatment of hemolysis in adults with cold agglutinin disease. Reata Pharmaceuticals, Inc. (NASDAQ: RETA ), as expected, received a complete response letter for its new drug application for bardoxolone methyl as a treatment option for Alport syndrome. An Adcom that met in early December voted against recommending approval of the drug.

AGIO, ALIM, and BV have been added to the Zacks Rank #5 (Strong Sell) List on March 1, 2022

AGIO, ALIM, and BV have been added to the Zacks Rank #5 (Strong Sell) List on March 1, 2022

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, to

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, toda

Agios Pharmaceuticals (AGIO) posts wider-than-expected loss for the fourth quarter of 2021. It does not record any revenues in the quarter.

Within the last quarter, Agios Pharmaceuticals (NASDAQ:AGIO) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 1 0 0

Agios Pharmaceuticals (AGIO) posts wider-than-expected loss for the fourth quarter of 2021. It does not record any revenues in the quarter.

Regeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics are included in this blog.

Agios Pharmaceuticals, Inc. (AGIO) CEO Jackie Fouse on Q4 2021 Results - Earnings Call Transcript